FSGS 360°: From Patient Experience to Precision Medicine

9 episodes

1.00 program credits

1h 03m

Details

Episodes

Presenters

Overview
Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Faculty:
Vladimir Tesar, MD, PhD
Head, Department of Nephrology
Charles University
Prague, Czech Republic

Advisor/Consultant: Calliditas, Otsuka, Roche, Stada, Travere

Meghan Sise, MD, MS
Director of Onconephrology
Associate Professor of Medicine 
Massachusetts General Hospital, Harvard Medical School
Boston, MA

Advisor/Consultant: Vera, Otsuka, Medibeacon, Merida Biosciences, Novartis, Relay Tx, Travere
Contracted Researcher: Otsuka, Gilead, Cabaletta, Novartis, Roche/Genetech, Merck
DSMB member: Alpine Immune sciences/Vertex
Speakers Bureau: Curio, TD Cowen

Kenneth Lieberman, MD
Chief, Pediatric Nephrology
Joseph M. Sanzari Children's Hospital
Hackensack University Medical Center
Hackensack, NJ

Dr. Lieberman has no relevant relationships to disclose.

Reviewers/Content Planners/Authors: 
Cindy Davidson has no relevant relationships to disclose. 
Anita Galdieri, PharmD has no relevant relationships to disclose. 
Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose. 
Learning Objectives
Upon completion of this activity, learners should be better able to:
Discuss the benefits and limitations of existing therapies used in managing patients with FSGS 
Evaluate the efficacy and safety of emerging therapies in adult and pediatric patients with FSGS 
Compare and contrast the antiproteinuric effects of DEARAs versus angiotensin II receptor antagonist in adult and pediatric patients with FSGS  
Apply evidence-based approaches for monitoring FSGS disease progression incorporating both clinical and patient-reported outcomes in managing adult and pediatric patients with FSGS
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with FSGS
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.  

Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

Global Learning Collaborative (GLC) designates this enduring activity for 1.0contact hour(s)/0.1 CEUs of pharmacy contact hour(s). 

The Universal Activity Number for this program is  JA0006235-0000-25-105-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).  

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until September 19, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.  
Provider(s)/Educational Partner(s)

Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant Travere Therapeutics, Inc. 
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited Reproduction of this material is not permitted without written permission from the copyright owner. 
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 09/19/2025
Expiration Date: 09/19/2026